Heat Biologics Inc. has filed to sell 3 million shares to raise $3 million, according to a filing with the Securities and Exchange Commission.

Heat Biologics is an immuno-oncology company in Durham developing therapies intended to activate a patient’s immune system to fight cancer.

The company filed a Form S-3 offering 3,020,084 shares of common stock issuable upon the exercise of the outstanding warrants issued to the investors in connection with the March 2016 follow-on public offering, at an exercise price of $1 per share.

The filing stated the proceeds of this offering will be used to fund clinical trials and for working capital and general corporate purposes as well as licensing or acquisition of assets complementary to its business.

On Dec. 1, Heat Biologics’ stock fell more than 50 percent during morning trading after the drug developer announced that its bladder cancer drug did not produce favorable results in a Phase 2 trial.

The stock was trading at $1.23, up 20 percent, as of 2 p.m., and hit a day high of $1.50 in the morning.